Скачать или смотреть Evaluating the potential of immunotherapy in dMMR/MSI-H CRC

Rocio Garcia-Carbonero, MD, PhD, University Hospital 12 De Octubre, Madrid, Spain, comments on mounting evidence that earlier treatment with immunotherapy is more effective in patients with dMMR/MSI-H colorectal cancer. Trials such as those involving dostarlimab, like AZUR-2 (NCT05855200), have shown maintenance of high levels of complete response in those previously treated with chemotherapy, radiotherapy, and surgery. This has major implications for quality of life, avoiding permanent colostomies and treatment-related toxicities. Although longer follow-ups and larger cohorts are needed to confirm curative outcomes, these approaches are already included in some clinical guidelines and are on the path to EMA approval. This interview took place at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancer 2025 Congress in Barcelona, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.